PDS Biotechnology 향후 성장
Future 기준 점검 0/6
PDS Biotechnology은 연간 수입과 매출이 각각 44.9%와 66% 증가할 것으로 예상되고 EPS는 연간 48%만큼 증가할 것으로 예상됩니다.
핵심 정보
44.9%
이익 성장률
48.00%
EPS 성장률
| Biotechs 이익 성장 | 25.4% |
| 매출 성장률 | 66.0% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 13 May 2026 |
최근 향후 성장 업데이트
Recent updates
새로운 내러티브 • Apr 02
Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 19
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 13
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
PDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.Seeking Alpha • Aug 24
PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.Seeking Alpha • Aug 04
PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.분석 기사 • Jul 08
PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • May 27
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients. Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established. PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.Seeking Alpha • Feb 22
PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 2 | -35 | -46 | N/A | 2 |
| 12/31/2027 | N/A | -35 | -39 | N/A | 2 |
| 12/31/2026 | N/A | -31 | -30 | N/A | 2 |
| 3/31/2026 | N/A | -33 | N/A | N/A | N/A |
| 12/31/2025 | N/A | -34 | -28 | -28 | N/A |
| 9/30/2025 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2025 | N/A | -37 | -34 | -34 | N/A |
| 3/31/2025 | N/A | -35 | -34 | -34 | N/A |
| 12/31/2024 | N/A | -38 | -35 | -35 | N/A |
| 9/30/2024 | N/A | -41 | -35 | -35 | N/A |
| 6/30/2024 | N/A | -41 | -34 | -34 | N/A |
| 3/31/2024 | N/A | -44 | -30 | -30 | N/A |
| 12/31/2023 | N/A | -43 | -34 | -34 | N/A |
| 9/30/2023 | N/A | -51 | -33 | -33 | N/A |
| 6/30/2023 | N/A | -48 | -31 | -31 | N/A |
| 3/31/2023 | N/A | -42 | -33 | -33 | N/A |
| 12/31/2022 | N/A | -41 | -26 | -26 | N/A |
| 9/30/2022 | N/A | -28 | -23 | -23 | N/A |
| 6/30/2022 | N/A | -28 | -22 | -22 | N/A |
| 3/31/2022 | N/A | -22 | -15 | -15 | N/A |
| 12/31/2021 | N/A | -17 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -13 | N/A |
| 6/30/2021 | N/A | -12 | -9 | -9 | N/A |
| 3/31/2021 | N/A | -14 | -14 | -14 | N/A |
| 12/31/2020 | N/A | -15 | -13 | -13 | N/A |
| 9/30/2020 | N/A | -15 | -14 | -14 | N/A |
| 6/30/2020 | N/A | -17 | -17 | -17 | N/A |
| 3/31/2020 | N/A | -18 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -7 | N/A | -18 | N/A |
| 9/30/2019 | N/A | -5 | N/A | -13 | N/A |
| 6/30/2019 | N/A | 0 | N/A | -9 | N/A |
| 3/31/2019 | N/A | 4 | N/A | -5 | N/A |
| 12/31/2018 | N/A | -4 | N/A | -2 | N/A |
| 9/30/2018 | N/A | -2 | N/A | -2 | N/A |
| 12/31/2017 | N/A | -3 | N/A | -3 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: PDSB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: PDSB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: PDSB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: PDSB 은(는) 내년에 수익이 없을 것으로 예상됩니다.
고성장 매출: PDSB 은(는) 내년에 수익이 없을 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: PDSB의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 22:01 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
PDS Biotechnology Corporation는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |